The company plans to target both domestic as well as export markets with the anthelmintic drug, the production of which will commence from August 2021
Lasa Supergenerics, which is into the manufacturing of veterinary and human APIs in India through its catalyst chemistry expertise and fully backward integrated unit, has launched Oxyclozanide.
Oxyclozanide is an anthelmintic, it is used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle (especially buffalos on the farm), sheep, and goats. For this, the company is setting up capacity in a brownfield expansion at its Chiplun unit. The total capacity would be 20 MT and would be funded through internal accruals. The company is committed to funding the entire capex through internal accruals. The production would start from August 2021.
Dr Omkar Herlekar, CMD, Lasa Supergenerics said, “Oxyclozanide is an anthelmintic. It has a huge opportunity both in domestic as well export markets. The additional capacity is being put within the existing facility at Chiplun, Maharashtra. We would be targeting both domestic and export markets. We are excited about the launch of Oxyclozanide as it fit our product selection criteria and we are confident of grabbing a significant market share. The company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.”
